Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China:a real-world assessment

作     者：Yongquan Peng Xujian Cao Yating Wang Weiwei Yu Ziwei Zeng Min Wang 

作者机构：Graduate Collaborative Training Base of the First Hospital of ChangshaUniversity of South ChinaHengyangHunan 421001China Institute of HIV/AIDSFirst Hospital of ChangshaChangshaHunan 410000China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第22期

页      面：2738-2740页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100401[医学-流行病与卫生统计学] 10[医学] 

基　　金：supported by the Research project of Hunan Provincial Department of Science and Technology(No.2020SK21361) 

主　　题：regimen drugs approval 

摘      要：To the Editor:Human immunodeficiency virus(HIV)epidemic poses a significant challenge to global public health.As of 2022,approximately 39.0 million people worldwide were living with HIV.[1]With the ongoing evolution of combined antiretroviral therapy(cART),HIV infection has transformed into a manageable chronic disease requiring long-term treatment.Among the various classes of antiretroviral(ARV)drugs,integrase strand transfer inhibitor(INSTI)-based regimens,known for potency and tolerability,have emerged as the predominant treatment modality worldwide.The nextgeneration of INSTI,bictegravir(BIC),received the Food and Drug Administration(FDA)approval in 2018 as a single-tablet regimen(STR)containing BIC(50 mg)/emtricitabine(FTC,200 mg)/tenofovir alafenamide(TAF,25 mg)for once daily.It has been endorsed as the preferred choice for treatment-naive patients by major guidelines,including the 2021 edition of the China Acquired Immune Deficiency Syndrome(AIDS)Diagnosis and Treatment Guidelines.[2]In China,people living with HIV(PLWH)are provided with flexible cART options,including the National Reimbursement Drug List(NRDL),self-pay drugs,and free drugs.Since being included in NRDL in 2021,BIC/FTC/TAF have gained popularity among an increasing number of patients.